TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Nov 30, 2022 09:31 JST
Source:
Biogen
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world's most prestigious peer-reviewed medical journals. For the details of the paper, please refer to: www.nejm.org/doi/full/10.1056/NEJMoa2212948.
The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission. Eisai and Biogen remain committed to disclosing data and information on lecanemab. If approved, we will work to bring the drug expeditiously to people living with early AD and their families.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully gain health authority approval.
For more information, visit www.eisai.com/news/2022/pdf/enews202284pdf.pdf.
Source: Biogen
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
More Press release >>
Latest Press Release
SPARX Group Establishes "Mirai Creation Fund IV" Toyota Motor Corporation, Sumitomo Mitsui Banking Corporation, MUFG Bank, Ltd. and Mizuho Bank, Ltd. to Provide Capital Targeting Total Commitments of JPY100 billion
May 12, 2026 19:29 JST
JCB and Credit Card Association of the Philippines (CCAP) Launch Partnership to Boost Financial Literacy Among Filipinos
May 12, 2026 14:00 JST
Aleen Inc. Announces Its OTC Market Listing
May 12, 2026 10:30 JST
Fujitsu Digitalizes Management of Japan's Reserve Self-Defense Force for Ministry of Defense, Enhancing Efficiency
May 07, 2026 14:02 JST
ULVAC Establishes Japan-Based Production for Rare-Earth Magnet Vacuum Melting Furnaces
May 01, 2026 11:00 JST
teamLab Borderless Ranked Among the World's 100 Most Visited Art Museums and 4th in Japan
Apr 30, 2026 21:00 JST
TANAKA to Showcase Advanced Semiconductor Materials and Circular Economy Initiatives at SEMICON Southeast Asia 2026
Apr 28, 2026 21:00 JST
NEC Launches "Africa Corporate Innovation Program" Accelerating Business Through Co-Creation with African Startups
Apr 28, 2026 19:05 JST
Advancing Early Detection: OMRON Healthcare Supports May Measurement Month 2026
Apr 28, 2026 01:00 JST
NEC Announces Strategic Collaboration with Anthropic Focused on Enterprise AI
Apr 23, 2026 17:46 JST
Fujitsu and Carnegie Mellon University launch joint center for Physical AI
Apr 23, 2026 17:19 JST
China Gas Signs Strategic Cooperation Agreement with CITIC Construction and China CITIC Bank
Apr 22, 2026 21:32 JST
CBL International Limited Acquires Majority Stake in Green Marine Energy Holdings Limited
Apr 22, 2026 21:15 JST
OMRON Healthcare and Tricog Health strengthen collaboration in India with Tricog CardioCheck (TCC)
Apr 22, 2026 19:30 JST
MHI Marine Machinery & Equipment and Mitsubishi Shipbuilding Obtain Approval in Principle (AiP) for the Basic Design of a Methane Oxidation Catalyst System for Marine LNG-Fueled Engines from Classification Society ClassNK
Apr 22, 2026 17:16 JST
NEC Receives Company of the Year recognition in Global Biometric Solutions from Frost & Sullivan
Apr 22, 2026 14:46 JST
MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kagoshima City
Apr 22, 2026 11:13 JST
MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Sendai City
Apr 22, 2026 11:03 JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 21, 2026 20:52 JST
Hitachi to establish a new company with Nojima under a strategic partnership to accelerate growth of its home appliance business
Apr 21, 2026 19:21 JST
More Latest Release >>